Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,934 | -1,174 | -75,801 | -66,700 | -47,964 |
| Depreciation Amortization | 42 | 21 | 1,056 | 766 | 537 |
| Accounts payable and accrued liabilities | -3,442 | -3,781 | 2,193 | 5,139 | 4,007 |
| Other Working Capital | -3,172 | -4,363 | -4,923 | 4,807 | 4,994 |
| Other Operating Activity | -10,961 | -5,251 | 314 | 694 | 131 |
| Operating Cash Flow | $-21,467 | $-14,548 | $-77,161 | $-55,294 | $-38,295 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 80 | N/A | 5 | 5 | 5 |
| Investing Cash Flow | $80 | $0 | $5 | $5 | $5 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 9 | N/A | 34,211 | 34,551 | 6,163 |
| Financing Cash Flow | $9 | $N/A | $34,211 | $34,551 | $6,163 |
| Beginning Cash Position | 29,109 | 29,109 | 72,054 | 72,054 | 72,054 |
| End Cash Position | 7,731 | 14,561 | 29,109 | 51,316 | 39,927 |
| Net Cash Flow | $-21,378 | $-14,548 | $-42,945 | $-20,738 | $-32,127 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,467 | -14,548 | -77,161 | -55,294 | -38,295 |
| Capital Expenditure | 0 | N/A | -7 | -7 | -7 |
| Free Cash Flow | -21,467 | -14,548 | -77,168 | -55,301 | -38,302 |